hepatocellular tumor tissues; adjacent non-tumorous tissue samples; mouse xenograft tumor tissues; pulmonary tissues
SNU-387; Hep3B; Huh7; MHCC97L; LO2; HUVECs
cell line-derived xenograft
ceRNA regulation (other); proliferation (promotes); cell cycle (promotes); angiogenesis (promotes); migration (promotes); invasion (promotes); metastasis (promotes)
RNase R Treatment; RT-qPCR; Microarray; FISH / smFISH; Clinical Sample Validation; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Cell Cycle Assay; Transwell Assay; Wound Healing Assay; Tube Formation Assay; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); Western Blot; Cohort Study; Survival Analysis; Bioinformatics Analysis
High hsa_circ_0000519 expression correlated with poor prognosis, advanced T classification, lymph node metastasis, and tumor differentiation in HCC patients; it was proposed as a potential therapeutic target for HCC treatment.
hsa_circ_0000519 is up-regulated in HCC tissues and cell lines and its high expression is associated with poor prognosis and adverse clinicopathological features. Functionally, it promotes HCC cell proliferation, cell cycle progression, migration, invasion, angiogenesis, tumor growth, and metastasis. Mechanistically, hsa_circ_0000519 sponges miR-1296 to up-regulate E2F7, forming a hsa_circ_0000519/miR-1296/E2F7 axis with potential therapeutic relevance.
0.8498
Circular RNA hsa_circ_0000519 contributes to angiogenesis and tumor progression in hepatocellular carcinoma through the miR-1296/E2F7 axis.
combined biological and clinical study